The Wall Street Journal on Tuesday examined a breast cancer screening device called the “Halo system,” which extracts a fluid from the nipple to test for “atypical” cells that are believed to be a precursor to cancer and has been nicknamed “the breast pap.”

The device — developed and sold by NeoMatrix of Irvine, Calif. — extracts the fluid called nipple aspirate using a warming technique and small suction cups. The test is noninvasive and lasts about five minutes, according to the Journal. The company estimates that atypical cells will be found in about 1% of women who undergo the procedure.

Link